Iovance's TIL Therapy Shows 50% Response Rate in Advanced Sarcomas

Event summary

  • Iovance's lifileucel achieved a 50% objective response rate in a pilot trial for advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
  • The trial involved six evaluable patients with significant disease burden and prior therapy resistance.
  • Iovance plans to initiate a single-arm registrational trial in Q2 2026 and engage with the FDA for accelerated approval.
  • UPS and DDLPS affect over 8,000 patients annually in the U.S. and Europe, with high unmet medical need in the second-line setting.

The big picture

Iovance's positive data in advanced sarcomas highlights the potential of TIL therapy to address a high-unmet need in aggressive cancers. The results position lifileucel as a potential disruptor in the sarcoma treatment landscape, where current second-line options offer limited efficacy. The strategic move to engage with the FDA for accelerated approval underscores Iovance's push to expand its TIL platform beyond its approved indication in melanoma.

What we're watching

Regulatory Pathway
Whether the FDA will accept the planned single-arm trial as sufficient for accelerated approval.
Clinical Expansion
The pace at which Iovance can expand lifileucel into other high-grade sarcoma subtypes.
Market Opportunity
How the 50% response rate positions lifileucel against existing second-line chemotherapy options.

Related topics

Biotechnology